Following an announcement last week from Food and Drug Administration (FDA) Commissioner Scott Gottlieb about pending agency action on generic drug competition, a draft of an alleged White House executive order about drug pricing has leaked. However, a White House spokesperson has said that the leaked draft is a fake. The leaked draft order aims […]
Read MoreOn June 13, 2017, the Senate Health, Education, Labor, & Pensions (HELP) Committee held a hearing to discuss the cost of prescription drugs, in particular how the drug delivery system affects what patients pay. The hearing was held after a request from a bipartisan group of senators led by Senators Al Franken (D-MN) and Bill […]
Read MoreOn January 4, 2017, the Department of Health and Human Services (HHS) released the 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties final rule. This rule implements a provision of the Affordable Care Act (ACA) that required HHS to publish the methods for calculating 340B ceiling prices and also imposes civil monetary […]
Read MoreOn September 21, 2016, the U.S. House Oversight and Government Reform Committee held a hearing to discuss the rising price of EpiPens. The two witnesses at this hearing were Heather Bresch, the Chief Executive Officer of Mylan, Inc., and Dr. Doug Throckmorton, the Deputy Director of the Center for Drug Evaluation and Research at the […]
Read More